Literature DB >> 8074459

Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts.

D S Gridley1, S N Hammond, B H Liwnicz.   

Abstract

Recent reports indicating that tumor necrosis factor-alpha (TNF-alpha) can augment the lethal effects of radiation against certain tumor cell lines prompted us to investigate whether this premise holds true for human colon tumor xenotransplants. Nude mice implanted s.c. with LS174T adenocarcinoma cells (day 0) were randomized into 4 groups: 1) no treatment; 2) TNF-alpha at 1 x 10(4) units/i.v. injection on days 1, 4, 8, and 10; 3) radiation at 4 Gy delivered on days 2, 5, 9, and 11; and 4) TNF-alpha + radiation administered using the same time-dose schedules as for groups 2 and 3. A decrease in tumor growth was obtained with radiation, but not TNF-alpha, as a single modality. However, significanty slower tumor growth was observed with TNF-alpha + radiation when compared to radiation alone. Blood and spleen cells from animals receiving both modalities exhibited the highest oxidative burst capacity. Histopathological evaluation showed large areas of necrosis in animals treated with radiation and with combined radiation + TNF-alpha, and only small areas of necrosis in animals treated with TNF-alpha alone. Necrosis in TNF-alpha-treated animals was not significantly larger than in controls. Irradiation of LS174T cells in culture generally decreased soluble TNF-alpha receptor and carcinoembryonic antigen in cell supernatants, but TNF-alpha was not detectable, regardless of radiation. The results show that pretreatment with TNF-alpha can significantly enhance the effects of radiation against human colon tumor xenografts and that the mechanisms of action may be related to increased oxygen radical production when both agents are administered and/or to induction of apoptosis by TNF-alpha. This data provides support for further investigations using TNF-alpha as an adjunctive agent in the radiotherapy of colon and other cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074459

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Authors:  Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

2.  A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Authors:  Deborah Citrin; Kevin Camphausen; Bradford J Wood; Martha Quezado; John Denobile; James F Pingpank; Richard E Royal; H Richard Alexander; Geoffrey Seidel; Seth M Steinberg; Yvonne Shuttack; Steven K Libutti
Journal:  Oncology       Date:  2011-03-25       Impact factor: 2.935

3.  [The demonstration of the radiation-induced production of tumor necrosis factor-alpha in Ewing's sarcoma RM 82 in vitro and in vivo].

Authors:  C Rübe; C Finke; F van Valen; K L Schäfer; B Dockhorn-Dworniczak; N Willich
Journal:  Strahlenther Onkol       Date:  1997-08       Impact factor: 3.621

4.  Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.

Authors:  D Azria; C Larbouret; V Garambois; A Kramar; P Martineau; B Robert; N Aillères; M Ychou; J B Dubois; A Pèlegrin
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.